Starpharma & Okamoto Industries Inc

Starpharma & Okamoto Industries Inc

Medical applications and devices are an expanding area of Australia-Japan business. The ASX-listed Starpharma’s core technology is “built around dendrimers, a type of synthetic nanoscale polymer that is highly regular in size and structure, and well-suited to pharmaceutical and medical uses.” Starpharma has announced it’s received regulatory approval in Japan for its VivaGel® condom, and has worked with Okamoto Industries Inc, the country’s largest condom manufacturer, on the product. Established in 1934, Okamoto manufactures a diverse range of industrial goods and lifestyle products, and has a consolidated group turnover of over AUD $1 billion.